Furthermore, it will be interesting to determine other actionable mutations of DLBCL in ctDNA, such as MYD88 and CD79B, together with EZH2 mutations in ctDNA, and analyze their impact in response to therapy and other clinical variables. Here, CD79B is linked to diffuse large B-cell lymphoma.